INTRODUCTION
Sarcoidosis is an immune-mediated multisystem granulomatous disease of unknown cause, defined by noncaseating granulomas and diagnosed by concordant clinical-radiologic findings with tissue confirmation after excluding mimics.[1] Although sarcoidosis is mainly interstitial, an alveolar (acinar) pattern is occasionally seen. Coalescent acinar opacities can produce segmental or peripheral, nonsegmental air-space consolidation with hazy, irregular margins, often with air bronchograms.[2] Alveolar sarcoidosis remains rare in the Indian cohort, and data suggest a prevalence of ~1.8%.[3] A decade ago, alveolar sarcoidosis presenting acutely with significant hypoxemia and progressing to respiratory failure was reported from India.[2] We present an adult woman with acute alveolar sarcoidosis, illustrating diagnostic pitfalls and a favorable response to timely corticosteroid therapy.
CASE REPORT
A 44-year-old nonsmoker homemaker female with no comorbidities presented with a history of shortness of breath, fever, and progressive cough for 5 days. Her symptoms started with dyspnea that worsened from mMRC grade 1–3 in a month. She had no symptoms of chest pain, loss of weight, loss of appetite, hemoptysis, joint pain, swelling of the hand and leg, or skin discoloration.
She had no history of tuberculosis (TB) infection or TB contact. General examination revealed no pallor, icterus, cyanosis, clubbing, lymphadenopathy, or skin changes. On arrival, she was alert and conscious with a heart rate of 112 bpm, blood pressure of 110/72 mmHg, respiratory rate 26/min, and hypoxic on room air with 86% saturation requiring oxygen of 5 L/min via face mask to maintain 95%.
Respiratory system examination revealed bilateral air entry with fine inspiratory crepitations heard in the bilateral mid and basal areas. The rest of the systemic examination was normal.
Chest X-ray (CXR) showed bilateral infiltrates [Figure 1a]. ECG was normal. The routine laboratory investigations, including total blood count, liver function, and kidney function tests, were within normal limits.
ESR (70 mmHg) and CRP (33.2 mg/L) were elevated. Empirical antibiotics with ceftriaxone and azithromycin were initiated. The throat swab for COVID-19 and Influenza polymerase chain reaction were negative.
Contrast-enhanced computed tomography (CECT) thorax showed multiple patchy subpleural consolidations with small peri-lymphatic nodules and interstitial thickening in bilateral mid and lower zones, with subcentimetric lymphadenopathy in the AP region. There was no evidence of pleural thickening, calcification, or effusion [Figure 1b]. Differential diagnosis included acute interstitial pneumonia, atypical pneumonia, organizing pneumonia, adenocarcinoma in situ, pulmonary lymphoma, pulmonary edema, and sarcoidosis.
Transthoracic echocardiography (2D) was normal. Serum brain natriuretic peptide, calcium, and Vitamin D levels were normal. 24-h urinary protein and calcium were normal.
Ultrasonography of the abdomen did not reveal any abnormality. The Mantoux test was negative. Serum ACE was 63 U/L (normal range: 7–56 U/L).
Blood and urine bacterial culture were negative. Rheumatoid factor, anti-CCP, antinuclear antibodies screening, extractable nuclear antigen panel, and cytoplasmic and perinuclear neutrophilic antibodies were negative. Spirometry revealed a restrictive pattern (Forced Expiratory Volume in 1 Second [FeV1]: 1.11 L [63% predicted], forced vital capacity [FVC]: 1.34 L [57% predicted], FEV1/FVC: 83%, DLCO [ml/min/mmHg] – 45%).
Bronchoalveolar (BAL) was obtained from the right middle lobe, and a transbronchial forceps biopsy from the right lower lobe. BAL cytology was lymphocytic (55%); while BAL Gram, acid–fast bacilli (AFB), Grocott staining (GMS), GeneXpert MTB, bacterial and KOH mount were negative. Histopathological examination showed alveolar tissue with focal interstitial epitheloid histiocytes, multinucleated giant cells, and noncaseating granulomas projecting into alveoli [Figure 1c and d].
Tissue Ziehl-Neelsen stain for AFB, GMS stain, and bacterial culture were negative. A final diagnosis of acute alveolar sarcoidosis was made considering raised serum ACE levels and noncaseating granuloma on histopathology. She was initiated on oral prednisone (0.5 mg/kg/day) with tapering doses.
Follow-up at the 6th month revealed symptomatic, radiological, and functional improvement. Spirometry revealed FeV1: 1.70 L (96%), FVC: 2.15 L (92%), FEV1/FVC: 79%. Serum ACE levels reduced to 33U/L.
Repeat chest radiograph [Figure 2a] and CT thorax [Figure 2b] showed near complete resolution of the parenchymal lesions after 6 months of treatment.
DISCUSSION
Sarcoidosis is a multisystem granulomatous disease of unknown cause, characterized by noncaseating granulomas. It affects all ages, gender, ethnicities, predominantly adults <40 years.[1] Danish registry data show an incidence of 14.5 per 100,000/year with peaks at age 30–39 in both gender.[4] Overall prevalence is ~60/100,000, with the highest rates in Black Americans, Swedes, and Danes. Diagnosis lacks a single biomarker and relies on clinical and radiologic features supported by histology.
The clinical presentations of sarcoidosis are broad and nonspecific, including symptoms such as fatigue, malaise, weight loss, and, less commonly, fever.[5]
Radiology shows typical bilateral symmetric hilar or mediastinal lymphadenopathy with perilymphatic nodules, interlobular septal and peribronchovascular thickening, and fibrosis. Atypical patterns include unilateral mediastinal lymph nodes (<5%), necrosis/cavitation (<1%), alveolar sarcoidosis with large ill-defined opacities (~5%), mass-like/solitary nodules, linear opacities, fibrocystic change, honeycombing, miliary nodules, bronchial wall nodularity, endobronchial granulomas, mosaic attenuation, and rare pleural disease (~1%).[16]
Airspace consolidation in sarcoidosis reflects coalescent acinar or interstitial nodules compressing or filling the alveoli. It was proposed by Felson, and supported by Reed and Madewell.[2] This pattern is known as the acinar or alveolar type of sarcoidosis.[1] It mimicks pneumonia, TB, malignancy, and organizing pneumonia. The reported prevalence is 1%–4.4% overall,[2] and 1.8% in India.[3] Battesti et al. reported predominance in men (69.6%), younger age (especially in the third decade of life), and a mean age of 28.4 ± 1.85 years.[7] It suggests an acute form, seen with mediastinal lymphadenopathy and previously normal CXR (last 1 year).
Approximately 10%–20% sarcoidosis patients show opacification of alveoli or airspaces radiologically.[28] It may present as acute hypoxemic respiratory failure, and it can clear rapidly radiologically with or without steroids.[2] For progressive, symptomatic disease with persistent pulmonary infiltration and declining lung function, treatment with systemic glucocorticoids (20–40 mg/day prednisone) is recommended. For refractory or recurrent cases, alternative agents include methotrexate, azathioprine, leflunomide, mycophenolate mofetil, rituximab, and hydroxychloroquine.[9]
CONCLUSION
Hypoxemic respiratory failure as the initial manifestation of pulmonary sarcoidosis is exceedingly rare. Primary care clinicians should suspect auto-immune causes such as alveolar sarcoidosis, in subacute dyspnea with bilateral airspace opacities unresponsive to antibiotics. Early diagnosis is crucial, as alveolar sarcoidosis typically demonstrates a quick clinical and radiological improvement with oral corticosteroids.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for her images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Conflicts of interest
There are no conflicts of interest.